The world's only implantable CGM — a sensor placed under the skin in your upper arm that monitors glucose for up to a full year without self-insertion.
Device specifications change frequently — always verify current information directly with the manufacturer before making any decisions. Full disclaimer.
New to Eversense? Start here.
Every other CGM on the market uses a self-inserted sensor you apply at home every 7–15 days. Eversense is completely different. A tiny sensor — about the size of a small pill — is implanted under the skin of your upper arm by a healthcare provider. It stays there for months, measuring glucose continuously. You never self-insert a sensor.
Eversense requires a clinical procedure. The sensor is inserted and removed by a trained healthcare provider in an office visit — not self-applied at home. You need a provider certified to perform the procedure to use this system.
A tiny sensor placed under the skin of your upper arm by a healthcare provider. Once inserted, it lasts up to 365 days — one sensor change per year, two office visits total.
A small rechargeable transmitter sits on top of your skin over the sensor site, held in place by a gentle silicone-based adhesive. It reads the implanted sensor and sends glucose data to your phone every 5 minutes. You change the adhesive daily.
Unique to Eversense — the transmitter vibrates on your arm when glucose goes high or low, even if your phone is across the room. No other CGM does this.
Shows real-time glucose readings, trend arrows, and history. Up to 5 caregivers can follow remotely via the app. Data syncs to Eversense DMS and Glooko for clinical review.
The earlier Eversense model. Sensor lasts 6 months, requiring two insertion procedures per year. Still available and fully supported, particularly in Europe.
Uses the same rechargeable transmitter and daily-change adhesive system as the 365. Sends readings to your phone every 5 minutes. Transmitter charges in 15 minutes daily.
The E3 requires one fingerstick calibration per day for the life of the sensor. This is one of its key differences from the 365, which reduces to weekly calibrations after day 13.
Same vibrating transmitter alert system as the 365. The arm buzzes when glucose crosses a high or low threshold — no phone required for this alert.
| Feature | Eversense E3 | Eversense 365 |
|---|---|---|
| Sensor duration | 180 days (6 months) | 365 days (1 year) |
| Procedures per year | 2 insertions, 2 removals | 1 insertion, 1 removal |
| Fingerstick calibration | 1 per day (daily) | Daily for first 13 days, then weekly |
| AID integration (US) | No | Yes (twiist) |
| On-body vibration alerts | Yes | Yes |
| MRI compatible | Yes (remove transmitter) | Yes (remove transmitter) |
| Caregiver sharing | Up to 5 followers | Up to 5 followers |
| FDA approval year | 2022 | 2024 |
With Eversense, there's no weekly or bi-weekly hassle of changing your sensor, you can't dislodge a sensor, and you reduce the number of supplies you need to carry or order.
— Senseonics CEO Tim Goodnow · via DiaTribe · diatribe.orgPatients frustrated by frequent sensor changes. Active patients who lose or dislodge sensors. Anyone with significant skin adhesive reactions to traditional CGMs. Patients who value discretion.
Requires office procedure. Patient must be willing to do calibrations (daily for E3, weekly for 365 after day 13). AID integration limited to twiist (365 only).
Insertion must be performed by a trained, certified provider. Procedure takes ~15 minutes under local anesthetic. Removal required before reinsertion — plan for annual (365) or semi-annual (E3) visits.
The only CGM sensor approved for use during an MRI — transmitter must be removed before scanning, but the implanted sensor itself is MRI-safe. Major clinical differentiator.
Once you're wearing Eversense, the day-to-day experience is genuinely different from any other CGM. Here's what to expect, what to manage, and what makes it work well.
The Transmitter RoutineThe transmitter sits over the sensor insertion site and is held on with a gentle silicone-based adhesive patch. You swap the patch daily — the transmitter itself stays. The silicone adhesive is designed to minimize skin reactions, a common frustration with other CGMs.
The transmitter has a rechargeable battery that needs about 15 minutes of charging per day. Build it into a routine — while showering, having coffee, or in the morning before you put it on. When it's off your body charging, there is no glucose data generated.
For the 365: four fingerstick calibrations in the first 24 hours, daily for the first 13 days, then once per week. For the E3: one fingerstick calibration every day. Calibrations keep the sensor accurate over its long lifespan.
After insertion, keep the wound dry and clean for five days. Avoid submerging the area. Once healed, the sensor itself is fully water-resistant — you can swim, shower, and sweat normally.
When glucose crosses a high or low alert threshold, your transmitter buzzes on your arm. No phone needed. No sound. This is particularly useful at night, in noisy environments, or anytime your phone is out of reach.
The system warns you if glucose is trending toward a high or low before it gets there — giving you time to act proactively rather than reactively.
Up to 5 caregivers can follow your glucose in real time via the Eversense Now app. They receive the same alerts you do, on their own devices.
All readings sync automatically to the cloud and are accessible via the Eversense DMS web portal. Compatible with Glooko for clinical data sharing at appointments.
The most common accuracy issue is missed calibrations. For E3: reinforce daily calibration habit. For 365: weekly after day 13, plus any time symptoms don't match readings. Missed calibrations degrade accuracy over time.
Assess the upper arm insertion site at each visit. Watch for signs of infection, migration, or scar tissue formation. Approved sites are limited to the upper arms — document which arm was used and plan the opposite arm for next insertion.
Patients lose data whenever the transmitter is off (charging, swimming, MRI, forgotten). Counsel patients that 15-min daily charging and consistent wearing maximizes Time in Range data quality for your reviews.
Eversense 365 integrates with the twiist AID system as of early 2026. Eversense E3 does not currently integrate with any AID system in the US. If patient wants AID, recommend upgrading to 365 or consider a different CGM.
For people who want to understand why Eversense works the way it does — and clinicians who need to explain it to patients, navigate coverage, or counsel on candidacy.
How It WorksEvery other CGM on the market uses electrochemical sensing — a tiny electrode that generates a current proportional to glucose concentration. Eversense uses a completely different technology: fluorescence.
The implanted sensor is coated with a glucose-binding chemistry that fluoresces (emits light) in proportion to the amount of glucose present. The transmitter reads this light signal through the skin and converts it to a glucose value.
Electrochemical sensors degrade quickly as they react with body chemistry — hence 10–15 day wear times. Fluorescence-based sensing is far more stable over time, enabling months or a year of accurate readings from a single implant.
The E3 uses a proprietary sacrificial boronic acid (SBA) design that reduces oxidation of the glucose-binding chemistry, extending sensor longevity from 90 days to 180 days compared to the original Eversense.
The implanted sensor is approximately 3.5mm × 18.3mm — roughly the size of a small paper match. It weighs about 0.06 grams. MARD: 8.5% for the E3 (PROMISE trial) and 8.8% for the 365 (ENHANCE trial) — comparable to leading surface-worn CGMs, achieved over a full year.
Only healthcare providers who have completed Senseonics' training and certification program can perform Eversense insertions and removals. Patients need to identify a certified provider in their area — not all endocrinology practices offer this.
A small incision is made in the upper arm under local anesthetic. The sensor is placed just beneath the skin using a custom inserter tool. The incision is closed with a small bandage. The procedure typically takes about 15 minutes and is not considered a surgical procedure — it's done in-office.
Both E3 and 365 have a 24-hour warmup period after insertion. For the 365: four fingerstick calibrations in the first 24 hours, then daily for 13 days, then weekly. For the E3: one fingerstick per day throughout.
Removal is also an in-office procedure — another small incision, sensor removal, and closure. Patients keep the insertion site dry for five days post-procedure. The opposite arm is typically used for the next insertion to avoid scar tissue buildup at the same site.
Key considerations for prescribing, managing, and following patients on Eversense CGM.
Fluorescence-based sensing — fundamentally different from electrochemical CGMs. E3 MARD: 8.5% (PROMISE trial, Diabetes Technology & Therapeutics 2022, n=181). 365 MARD: 8.8% (ENHANCE trial, Diabetes Technology & Therapeutics 2025, n=110). Alert detection in ENHANCE: 96.6% at 70 mg/dL, 97.9% at 180 mg/dL. 90% of 365 sensors survived full 365 days. No related serious adverse events in either pivotal study.
E3: 180 days (2 procedures/year). 365: 365 days (1 procedure/year). Both have 24-hr warmup post-insertion. Readings every 5 minutes. Data gap when transmitter is off.
E3: 1 fingerstick/day throughout. 365: 4 calibrations in first 24 hrs, daily for days 1–13, then weekly. Additional calibrations when symptoms ≠ readings or on interfering meds.
The only CGM sensor approved for MRI use. Transmitter must be removed before scanning. Implanted sensor is MRI-safe. Document this for patients who require frequent imaging (renal disease, oncology, etc.).
Eversense 365: iCGM-cleared; compatible with Sequel twiist AID system (widely available early 2026). Eversense E3: No AID integration in US. Future expansion expected.
Insertion site infection (minor but possible), scar tissue formation, sensor migration. Alternate arms at each reinsertion. Keep wound dry 5 days post-procedure. Certified provider required for all procedures.
Eversense DMS (web-based portal for clinicians). Compatible with Glooko. Eversense Now app for patient. Up to 5 remote followers via app. No Dexcom Follow or Clarity integration — different ecosystem from Dexcom/Abbott.
18+ (T1D or T2D on insulin). Frustrated with frequent sensor changes. Active lifestyle (sensor can't be dislodged). Significant adhesive skin reactions. Needs frequent MRI. Values discretion. Willing to calibrate.